TABLE 1.
Demographic characteristics of study patientsa
| Characteristic | Value |
|---|---|
| No. (%) of patients of the following sex: | |
| Male | 85 (56.7) |
| Female | 65 (43.3) |
| Mean age ± SD (yr) | 43.9 ± 7.2 |
| Mean body wt ± SD (kg) | 60.3 ± 11.9 |
| Mean body mass index ± SD (kg/m2) | 22.5 ± 3.6 |
| Mean serum creatinine concn ± SD (mg/dl) | 0.9 ± 0.2 |
| Mean eGFRb ± SD (ml/min/1.73 m2) | 90.3 ± 18.0 |
| No. (%) of patients: | |
| Hepatitis B virus antigen positive | 60 (40.0) |
| Hepatitis C antibody positive | 12 (8.0) |
| Mean duration of tenofovir treatment ± SD (yr) | 3.7 ± 2.0 |
| Mean tenofovir sampling time after last dose ± SD (h) | 11.9 ± 0.8 |
| Mean tenofovir plasma concn ± SD (ng/ml) | 100.3 ± 52.7 |
| No. (%) of patients receiving the following comedications: | |
| Lamivudine | 94 (62.7) |
| Emtricitabine | 46 (30.7) |
| Zidovudine | 10 (6.7) |
| Efavirenz | 91 (60.7) |
| Nevirapine | 10 (6.7) |
| Lopinavir-ritonavir | 17 (11.3) |
| Atazanavir-ritonavir | 9 (6.0) |
| Darunavir-ritonavir | 3 (2.0) |
| Saquinavir-ritonavir | 19 (12.7) |
| Raltegravir | 1 (0.7) |
a
Data are for 150 patients.
b
Calculated by use of the MDRD formula.